Effects of Long‐Term Drugs on Alfentanil Clearance in Patients Undergoing Renal Transplantation

Douglas E. Koehntop, Saleem E. Noormohamed, Courtney V. Fletcher

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although patients in renal failure frequently take several drugs on a long‐term basis, drug‐induced alterations in alfentanil metabolism have not been examined as a possible source of variability in alfentanil clearance in this population. We compared the pharmacokinetics of alfentanil during renal transplantation in seven patients receiving and six not receiving long‐term drug therapy. After the rapid intravenous injection of alfentanil 100 μg/kg during isoflurane anesthesia, plasma concentrations were measured at intervals up to 6 hours by radioimmunoassay. The terminal elimination half‐life, steady‐state volume of distribution (Vdss), and total body clearance were determined by non‐compartmental methods. There was no statistical difference in the Vdss between the two patient groups. However, clearance was significantly higher and elimination half‐life lower in the group taking long‐term drugs: clearance 6.94 ± 4.64 versus 3.47 ± 0.16 ml·kg−1·min−1, and elimination half‐life 50.6 ± 13.9 versus 90.7 ± 22.4 minutes, respectively (p<0.05). The higher clearance occurred even though five of the seven patients were taking agents known to be metabolized by the same cytochrome P‐450 hepatic isozyme that metabolizes alfentanil and therefore potential competitive inhibitors of alfentanil metabolism. Drugs taken by the three patients with the highest alfentanil clearances included known inducers of hepatic drug metabolism. Thus, in the presence of several long‐term drugs, the clearance of alfentanil appears to be noticeably increased by inducers of hepatic drug metabolism but unaffected by potential competitive inhibitors. 1994 Pharmacotherapy Publications Inc.

Original languageEnglish (US)
Pages (from-to)592-599
Number of pages8
JournalPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Volume14
Issue number5
DOIs
StatePublished - Jan 1 1994

Fingerprint

Alfentanil
Kidney Transplantation
Pharmaceutical Preparations
Half-Life
Liver
Drug Therapy
Isoflurane
Intravenous Injections
Cytochrome P-450 Enzyme System
Isoenzymes
Radioimmunoassay
Renal Insufficiency
Publications
Anesthesia
Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effects of Long‐Term Drugs on Alfentanil Clearance in Patients Undergoing Renal Transplantation. / Koehntop, Douglas E.; Noormohamed, Saleem E.; Fletcher, Courtney V.

In: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 14, No. 5, 01.01.1994, p. 592-599.

Research output: Contribution to journalArticle

@article{a9d1a5d3033e40699cc9ee9e8b6408ed,
title = "Effects of Long‐Term Drugs on Alfentanil Clearance in Patients Undergoing Renal Transplantation",
abstract = "Although patients in renal failure frequently take several drugs on a long‐term basis, drug‐induced alterations in alfentanil metabolism have not been examined as a possible source of variability in alfentanil clearance in this population. We compared the pharmacokinetics of alfentanil during renal transplantation in seven patients receiving and six not receiving long‐term drug therapy. After the rapid intravenous injection of alfentanil 100 μg/kg during isoflurane anesthesia, plasma concentrations were measured at intervals up to 6 hours by radioimmunoassay. The terminal elimination half‐life, steady‐state volume of distribution (Vdss), and total body clearance were determined by non‐compartmental methods. There was no statistical difference in the Vdss between the two patient groups. However, clearance was significantly higher and elimination half‐life lower in the group taking long‐term drugs: clearance 6.94 ± 4.64 versus 3.47 ± 0.16 ml·kg−1·min−1, and elimination half‐life 50.6 ± 13.9 versus 90.7 ± 22.4 minutes, respectively (p<0.05). The higher clearance occurred even though five of the seven patients were taking agents known to be metabolized by the same cytochrome P‐450 hepatic isozyme that metabolizes alfentanil and therefore potential competitive inhibitors of alfentanil metabolism. Drugs taken by the three patients with the highest alfentanil clearances included known inducers of hepatic drug metabolism. Thus, in the presence of several long‐term drugs, the clearance of alfentanil appears to be noticeably increased by inducers of hepatic drug metabolism but unaffected by potential competitive inhibitors. 1994 Pharmacotherapy Publications Inc.",
author = "Koehntop, {Douglas E.} and Noormohamed, {Saleem E.} and Fletcher, {Courtney V.}",
year = "1994",
month = "1",
day = "1",
doi = "10.1002/j.1875-9114.1994.tb02856.x",
language = "English (US)",
volume = "14",
pages = "592--599",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Effects of Long‐Term Drugs on Alfentanil Clearance in Patients Undergoing Renal Transplantation

AU - Koehntop, Douglas E.

AU - Noormohamed, Saleem E.

AU - Fletcher, Courtney V.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Although patients in renal failure frequently take several drugs on a long‐term basis, drug‐induced alterations in alfentanil metabolism have not been examined as a possible source of variability in alfentanil clearance in this population. We compared the pharmacokinetics of alfentanil during renal transplantation in seven patients receiving and six not receiving long‐term drug therapy. After the rapid intravenous injection of alfentanil 100 μg/kg during isoflurane anesthesia, plasma concentrations were measured at intervals up to 6 hours by radioimmunoassay. The terminal elimination half‐life, steady‐state volume of distribution (Vdss), and total body clearance were determined by non‐compartmental methods. There was no statistical difference in the Vdss between the two patient groups. However, clearance was significantly higher and elimination half‐life lower in the group taking long‐term drugs: clearance 6.94 ± 4.64 versus 3.47 ± 0.16 ml·kg−1·min−1, and elimination half‐life 50.6 ± 13.9 versus 90.7 ± 22.4 minutes, respectively (p<0.05). The higher clearance occurred even though five of the seven patients were taking agents known to be metabolized by the same cytochrome P‐450 hepatic isozyme that metabolizes alfentanil and therefore potential competitive inhibitors of alfentanil metabolism. Drugs taken by the three patients with the highest alfentanil clearances included known inducers of hepatic drug metabolism. Thus, in the presence of several long‐term drugs, the clearance of alfentanil appears to be noticeably increased by inducers of hepatic drug metabolism but unaffected by potential competitive inhibitors. 1994 Pharmacotherapy Publications Inc.

AB - Although patients in renal failure frequently take several drugs on a long‐term basis, drug‐induced alterations in alfentanil metabolism have not been examined as a possible source of variability in alfentanil clearance in this population. We compared the pharmacokinetics of alfentanil during renal transplantation in seven patients receiving and six not receiving long‐term drug therapy. After the rapid intravenous injection of alfentanil 100 μg/kg during isoflurane anesthesia, plasma concentrations were measured at intervals up to 6 hours by radioimmunoassay. The terminal elimination half‐life, steady‐state volume of distribution (Vdss), and total body clearance were determined by non‐compartmental methods. There was no statistical difference in the Vdss between the two patient groups. However, clearance was significantly higher and elimination half‐life lower in the group taking long‐term drugs: clearance 6.94 ± 4.64 versus 3.47 ± 0.16 ml·kg−1·min−1, and elimination half‐life 50.6 ± 13.9 versus 90.7 ± 22.4 minutes, respectively (p<0.05). The higher clearance occurred even though five of the seven patients were taking agents known to be metabolized by the same cytochrome P‐450 hepatic isozyme that metabolizes alfentanil and therefore potential competitive inhibitors of alfentanil metabolism. Drugs taken by the three patients with the highest alfentanil clearances included known inducers of hepatic drug metabolism. Thus, in the presence of several long‐term drugs, the clearance of alfentanil appears to be noticeably increased by inducers of hepatic drug metabolism but unaffected by potential competitive inhibitors. 1994 Pharmacotherapy Publications Inc.

UR - http://www.scopus.com/inward/record.url?scp=0028109024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028109024&partnerID=8YFLogxK

U2 - 10.1002/j.1875-9114.1994.tb02856.x

DO - 10.1002/j.1875-9114.1994.tb02856.x

M3 - Article

C2 - 7997393

AN - SCOPUS:0028109024

VL - 14

SP - 592

EP - 599

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5

ER -